MiMedx Group, Inc. (MDXG)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, MiMedx Group, Inc. currently loses $23.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
MiMedx’s revenue topped consensus despite a sharp year-over-year decline, based on preliminary results for the second fiscal quarter of 2026 that were reported July 29, 2026. Revenue fell 34.7% to about $64.4 million (down from $98.6 million a year ago), yet still topped expectations, coming in at $64.4 million versus the $63.5 million estimate (+1.4%). Gross profit was roughly $44.4 million, with gross margin at 69.0%. The company generated negative operating cash flow of about $10.0 million during the quarter, and it repurchased roughly $12.6 million of stock. Next-period consensus calls for EPS of -$0.01 on revenue of $69.6 million.
About MiMedx Group, Inc.
MiMedx Group, Inc. develops and markets placental tissue allografts for wound care, surgical recovery, burn treatment, and related uses in the U.S. healthcare and biotechnology fields. Listed on NASDAQ as MDXG, the company recorded $418.6 million in revenue in FY2025.
Today's Snapshot
MDXG started the session flat at 4.68, while its sector was flat.
Trading Volume
Below 10d avg (881.9K)
363.8K
vs S&P 500 Today
Underperforming Market
-2.29%
Updated: September 10, 2026 at 15:04 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$4.29 - $4.96Buy
- RSI (14)57.61Neutral
- Stochastic %K (14, 3, 3)76.75Neutral
- MACD Level (12, 26)0.10Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.